Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2003
05/27/2003US6569841 Administering a dextran that has been modified by covalent bonding of charged groups opposite that of a charged tumor
05/27/2003US6569834 Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
05/27/2003US6569833 Given amino acid sequence; useful treating hyperproliferative disorders and in drug screening and drug design
05/27/2003US6569666 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
05/27/2003US6569665 Genetic engineering; enzymatic inhibitor screening; use of calpain inhibitors in treatment of neurodegenerative disease
05/27/2003US6569655 For use in therapeutics, diagnostics, and as research tools
05/27/2003US6569638 Method for screening compounds for the treatment of neoplasia
05/27/2003US6569463 Encapsulation coat includes different combinations of pharmaceutical active ingredients, hydrophilic and lipophilic surfactants, and triglycerides
05/27/2003US6569428 For regulating angiogenesis; nucleic acid encoding an endothelial cell mitogen and endothelial cell progenitors, where the EC progenitors are CD34+, Flk-1+, and tie-2+
05/27/2003US6569424 A probiotic formulation of Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799); containing at least one volatile fraction (VF) of a plant extract
05/27/2003US6569420 Human interferon-ε: a type I interferon
05/27/2003US6569195 Stent coating
05/27/2003US6569075 Lipoxin compounds and their use in treating cell proliferative disorders
05/27/2003CA2213054C Novel bis(imido) derivatives, a process for their preparation and pharmaceutical compositions containing them
05/27/2003CA2199747C 2',5' phosphorothioate/phosphodiester oligoadenylates and antiviral uses thereof
05/27/2003CA2176229C Improved interferon polymer conjugates
05/27/2003CA2158455C Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide and their uses in vaccines and disease treatments
05/27/2003CA2140866C Use of inhibitors of fatty acid synthesis for treating cancer
05/27/2003CA2031430C Process for refolding recombinantly produced tgf-.beta.-like proteins
05/22/2003WO2003042390A1 Mammalian protein phosphatases
05/22/2003WO2003042377A1 Expansion of t cells in vitro and expanded t cell populations
05/22/2003WO2003042358A2 Methods of using 48149, a human aminopeptidase family member
05/22/2003WO2003042357A2 Enzymes
05/22/2003WO2003042344A2 Apo2 ligand/trail formulations
05/22/2003WO2003042247A2 Modified anti-tnf alpha antibody
05/22/2003WO2003042246A2 Inhibitors of the notch signalling pathway for use in the treatment of cancer
05/22/2003WO2003042243A2 Immunogenic alk (anaplastic lymphoma kinase) peptides
05/22/2003WO2003042216A1 Polycyclic guanine derivative phosphodiesterase v inhibitors
05/22/2003WO2003042214A2 A2b adenosine receptor antagonists
05/22/2003WO2003042197A1 Oligopeptides and compositions containing them as cathepsin s inhibitors
05/22/2003WO2003042191A1 Benzamide and heteroarylamide as p2x7 receptor antagonists
05/22/2003WO2003042190A1 N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
05/22/2003WO2003042187A1 Serin protease inhibitors
05/22/2003WO2003042176A1 Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation
05/22/2003WO2003042174A1 Cannabinoid receptor ligands
05/22/2003WO2003042172A2 C-5 modified indazolylpyrrolotriazines
05/22/2003WO2003042171A1 Vitamin d derivatives with acyloxy groups at the 24-position of the side chain, a method for producing the same and use thereof in production of medicaments
05/22/2003WO2003042113A1 Production of cell suspensions
05/22/2003WO2003041740A1 Tumor necrosis agent
05/22/2003WO2003041739A1 Anticaner agents
05/22/2003WO2003041736A2 Method for the treatment of cardiotoxicity induced by antitumor compounds
05/22/2003WO2003041726A1 Use of an extracellular adherence protein for the manufacture of an anti-inflammatory drug
05/22/2003WO2003041721A1 Process for reacting alkaloids and use of the reaction products in the preparation of medicaments
05/22/2003WO2003041717A1 Persistent filmy preparation for topical administration containing prostaglandin derivative
05/22/2003WO2003041715A1 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
05/22/2003WO2003041708A1 Benzimidazoles useful as protein kinase inhibitors
05/22/2003WO2003041707A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
05/22/2003WO2003041702A1 Production of pure stereoisomers of tricyclo[5.2.1.02.6]-dec-9-yl xanthogenate and medicaments therefrom
05/22/2003WO2003041695A1 Method and pharmaceutical preparations for reducing the activity of cells
05/22/2003WO2003041689A1 Biocompatible polymer blends and uses thereof
05/22/2003WO2003041660A2 Solubilized topoisomerase poisons
05/22/2003WO2003041658A2 Process for the preparation of 3,7-disubstituted-2,3,4,5- tetrahydro-1h-1,4-benzodiazepine compounds
05/22/2003WO2003041653A2 Cytotoxic agents
05/22/2003WO2003041649A2 Cyanoalkylamino derivatives as protease inhibitors
05/22/2003WO2003041642A2 Polymeric thiol-linked prodrugs employing benzyl elimination systems
05/22/2003WO2003041563A2 Neurotransmitter balance chemotherapy
05/22/2003WO2003022280A3 3-glyoxlylamideindoles for treating cancer
05/22/2003WO2003020763A3 Soluble t cell receptor
05/22/2003WO2003020699A3 Tyrosine kinase inhibitors
05/22/2003WO2003016464A3 Cancer specific oligosaccharide sequences and use thereof
05/22/2003WO2003011277A3 Methods to mobilize progenitor/stem cells
05/22/2003WO2003007883A3 Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
05/22/2003WO2002100353A3 Cd10-activated prodrug compounds
05/22/2003WO2002100327A3 Substituted 1-benzazepines and derivatives thereof
05/22/2003WO2002098438A9 Compositions containing an active fraction isolated from scutellariae barbatae and methods of use
05/22/2003WO2002097116A3 Delivery system for nucleic acids
05/22/2003WO2002089802A3 Use of neurokinin receptor antagonists to treat androgen-dependent diseases
05/22/2003WO2002078766A3 Combination therapy
05/22/2003WO2002068653A3 Tri-hybrid melanoma antigen
05/22/2003WO2002056912A3 Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
05/22/2003WO2002053740A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/22/2003WO2002053141A3 Inhibition of angiogenesis by nucleic acids
05/22/2003WO2002051430A3 Methods of modulating toll-related receptor (trr) signaling
05/22/2003WO2002044183A3 Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
05/22/2003WO2002044168A3 Indole-type inhibitors of p38 kinase
05/22/2003WO2002041844A9 Chemotherapeutic composition using nanocrystalline calcium phosphate paste
05/22/2003WO2002039958A9 Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
05/22/2003WO2002030924A9 Quinazoline derivatives with anti-tumour activity
05/22/2003WO2002024187A3 Treatment of diseases with adamantane derivatives
05/22/2003WO2002024146A3 Methods of decreasing or preventing pain using spicamycin derivatives
05/22/2003WO2001070941A9 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
05/22/2003WO2001068708A9 Human and humanized fap-alpha-specific antibodies
05/22/2003US20030097023 For prophylaxis and therapy of immunological diseases, asthma, abnormal bone formation, neuronal cell death, lung failure, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardiac ischemia
05/22/2003US20030096998 As immunomodulators and for inducing cytokine biosynthesis in animals, for therapy of viral infections
05/22/2003US20030096992 Method of preparing alkylated salicylamides via a dicarboxylate intermediate
05/22/2003US20030096858 The parent drug compound is modified by forming one or more of predetermined chemical arrangement within parent drug structure for programming specific course and rate of metabolism for drug that leads to inactive nontoxic metabolite
05/22/2003US20030096852 Inhibiting binding interaction between hGH (human growth hormone) or a mutant thereof and an hGH binding protein or receptor in mammal administering benzimidazole compound
05/22/2003US20030096844 Cannabinoid receptor ligands
05/22/2003US20030096842 Inhibitors of farnesyl protein transferase
05/22/2003US20030096841 For treatment of cancers, heart disease, such as congestive heart failure, osteoporosis, genetic, inflammatory, allergic, and autoimmune diseases
05/22/2003US20030096836 2-Aroylimidazole compounds for treating cancer
05/22/2003US20030096829 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors
05/22/2003US20030096827 Heterocyclic amine derivatives; for treating an inflammatory or immune disease, a cardiovascular disease, or a neurodegenerative condition
05/22/2003US20030096824 Substituted phenylamidines medicaments containing said compounds and method for production thereof
05/22/2003US20030096823 Method for the treatment of cardiotoxicity induced by antitumor compounds
05/22/2003US20030096819 Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents
05/22/2003US20030096817 Inhibiting mammalian protein kinases (p38) with (2,6-difluoro-phenyl)-(5-iodo-pyridin-2-yl)amine for treatment of cardiovascular disorders
05/22/2003US20030096816 Such as 2-methylsulfanyl-5-(2-phenylamino-pyrimidin-4-yl)-4-p-tolyl-thiophene-3 -carbonitrile; antiproliferative agents; stents
05/22/2003US20030096796 N-cyanomethyl amides which are cysteine protease inhibitors; use treating diseases associated with activity of cathepsins B, K, L or S such as autoimmune disorders, allergic disorder, allogeneic immune response, cardiovascular disorders
05/22/2003US20030096789 For example, camptothecin derivatives such as irinotecan with capecitabine, gemcitabine or multi-targeted antifolate (MTA), also known as pemetrexed
1 ... 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 ... 2211